Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
3 studies found for:    15284112 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Phase I Extension Trial of Repeated Infusions of ISF35
Condition: Chronic Lymphocytic Leukemia
Intervention: Biological: ISF35
2 Completed A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)
Condition: Chronic Lymphocytic Leukemia
Intervention: Biological: ISF35
3 Active, not recruiting FCM Versus R-FCM Followed by R-Maintenance or Observation Only
Conditions: Lymphoma, Follicular;   Lymphoma, Low-Grade;   Lymphoma, Intermediate-Grade
Interventions: Procedure: FCM;   Procedure: R-FCM;   Drug: rituximab maintenance;   Other: observation only

Indicates status has not been verified in more than two years